Case Report: A case of a pregnancy-associated breast cancer patient with a pathogenic variant in BRCA1 who underwent staged risk-reducing salpingo-oophorectomy and contralateral risk-reducing mastectomy - Top-Institutions - MDSpire

Case Report: A case of a pregnancy-associated breast cancer patient with a pathogenic variant in BRCA1 who underwent staged risk-reducing salpingo-oophorectomy and contralateral risk-reducing mastectomy

  • By

  • Haruko Takuwa

  • Shoko Sasaki

  • Naoki Goda

  • Megumi Takeuchi

  • May 20, 2026

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Women’s College Research Institute
    Women’s College Research Institute

    Toronto, Ontario

    Key Differentiators

    • Oncology

  • #2

    University of Toronto
    University of Toronto

    Toronto, Ontario

    Key Differentiators

    • Oncology

  • #3

    IRCCS Ospedale Policlinico San Martino
    IRCCS Ospedale Policlinico San Martino

    Genoa, Liguria

    Key Differentiators

    • Oncology

  • #4

    Abramson Cancer Center
    Abramson Cancer Center

    Philadelphia, Pennsylvania

    Key Differentiators

    • Oncology

  • #5

    Perelman School of Medicine at the University of Pennsylvania
    Perelman School of Medicine at the University of Pennsylvania

    Philadelphia, Pennsylvania

    Key Differentiators

    • Oncology

Original Source(s)

Case Report: A case of a pregnancy-associated breast cancer patient with a pathogenic variant in BRCA1 who underwent staged risk-reducing salpingo-oophorectomy and contralateral risk-reducing mastectomy

  • by Haruko Takuwa, Shoko Sasaki, Naoki Goda, Megumi Takeuchi

  • May 20, 2026

Related Content

Rethinking Progress in Clinical Trials

Three clinical development leaders discuss how early signals, trial design, regulatory expectations, and patient access are reshaping clinical development

  • May 20, 2026

  • 11 min
Roswell Park Experts Report on Discovery of Rare Bladder Cells, Neural Mapping of Pelvic Floor Muscles at AUA 2026

Evidence provided by a Roswell Park study indicates that neoadjuvant chemotherapy may be the preferred course of treatment for patients with non-muscle-invasive bladder cancer (NMIBC) when their disease progresses and they are diagnosed with muscle-invasive bladder cancer (MIBC)

  • by

  • May 19, 2026

  • 7 min
This Week’s Biopharma News: FDA Commissioner Steps Down

Marty Makary’s resignation puts the agency under acting leadership, while BMS and Hengrui unveil a multibillion-dollar pipeline deal and GSK lines up a chronic hepatitis B launch in China.

  • May 19, 2026

  • 4 min